Sanofi Refuses To Refund Philippines For Used Dengvaxia Vaccines; Controversy Hurting Public Health Efforts In Country, As 3 Deaths Possibly Linked To Vaccine
Agence France-Presse: Dengue vaccine row wreaks havoc on Philippine war on disease
“Widespread fears over a controversial dengue vaccine that some blame for child deaths are wreaking havoc on the Philippines’ war on preventable diseases, with many parents refusing to get their children immunized, a senior health official said Friday…” (2/2).
Agence France-Presse: Sanofi rejects refund demand faces Philippine suit over dengue vaccine
“French pharmaceutical giant Sanofi on Monday rejected a Philippine government demand to return tens of millions of dollars paid for a dengue vaccine after the program was suspended over health concerns…” (2/5).
Associated Press: Sanofi rejects Philippine plea for refund on used vaccines
“…Health Secretary Francisco Duque III has said that Sanofi Pasteur has agreed to take back huge stocks of unused Dengvaxia and pay back more than a billion pesos ($20 million) to the Philippine government…” (Gomez, 2/5).
Reuters: Philippines says anti-dengue vaccine may be connected to three deaths
“The Philippines said on Friday the anti-dengue vaccine Dengvaxia may be connected to three deaths in the country, according to a government-ordered inquiry, and that the drug is not ready for mass immunization…” (Mogato, 2/3).
Wall Street Journal: Initial Philippines Probe Finds ‘Causal Association’ Between Deaths, Sanofi Dengue Vaccine
“…A government-ordered probe in the Philippines found a ‘causal association’ between inoculation and the deaths of at least three out of the 14 children who are a focus of its investigation. … The department cautioned that its results were preliminary…” (Rana, 2/2).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.